Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. (Q46789893)

From Wikidata

Jump to navigation Jump to search

scientific article published in November 2005

Language	Label	Description	Also known as
English	Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.	scientific article published in November 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16268823%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009 (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16268823%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16268823%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Umaporn Siangphoe

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16268823%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

K Ruxrungtham

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16268823%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

C J Duncombe

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16268823%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

M Stek

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16268823%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

J M A Lange

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16268823%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

D A Cooper

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16268823%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

P Phanuphak

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16268823%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

1 November 2005

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16268823%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16268823%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16268823%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16268823%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

410-420

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16268823%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00327.X

21 January 2018

A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00327.X

21 January 2018

Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00327.X

21 January 2018

Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00327.X

21 January 2018

Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00327.X

21 January 2018

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00327.X

21 January 2018

Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00327.X

21 January 2018

Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00327.X

21 January 2018

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00327.X

21 January 2018

Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00327.X

21 January 2018

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00327.X

21 January 2018

Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00327.X

21 January 2018

Combination antiretroviral therapy and the risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00327.X

21 January 2018

Blood pressure and high blood pressure. Aspects of risk

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00327.X

21 January 2018

Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00327.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46789893&oldid=1338714453"